Thus, ALA is considered effective in the amelioration of neuropathic impairments in elderly insulin-treated patients with history of CVD in whom weight and blood pressure are well controlled, as well as in those with more severe stages of diabetes and neuropathy, and HbA1c levels ≥7% (144). The gene discussed is INS; the disease is diabetes mellitus.